See more : HOOKIPA Pharma Inc. (HOOK) Income Statement Analysis – Financial Results
Complete financial analysis of Eloxx Pharmaceuticals, Inc. (ELOX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Eloxx Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- RenoWorks Software Inc. (RW.V) Income Statement Analysis – Financial Results
- Thales S.A. (THLEF) Income Statement Analysis – Financial Results
- Evolent Health, Inc. (EVH) Income Statement Analysis – Financial Results
- Dataproces Group A/S (DATA.CO) Income Statement Analysis – Financial Results
- Micropole S.A. (MUN.PA) Income Statement Analysis – Financial Results
Eloxx Pharmaceuticals, Inc. (ELOX)
About Eloxx Pharmaceuticals, Inc.
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 75.00K | 75.00K | 100.00K | 0.00 | 200.00K | 0.00 | 140.00K | 275.00K | 456.67K | 300.00K | 66.67K | 125.00K | 16.67K | 10.00K | 200.00K | 1.00 | 1.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -18.71K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 75.00K | 75.00K | 100.00K | 0.00 | 200.00K | 0.00 | 140.00K | 275.00K | 456.67K | 300.00K | 66.67K | 125.00K | 16.67K | 10.00K | 200.00K | 1.00 | 18.71K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 0.00% | 100.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 1,871,400.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 23.73M | 45.57M | 14.59M | 26.35M | 20.49M | 16.40M | 733.66K | 2.18M | 4.57M | 3.34M | 2.09M | 2.57M | 3.72M | 2.64M | 2.35M | 1.76M | 1.21M | 1.57M | 1.42M | 1.15M | 793.90K | 370.19K | 479.47K | 476.46K | 173.46K | 0.00 | 0.00 |
| General & Administrative | 10.69M | 20.45M | 14.85M | 24.21M | 26.48M | 2.70M | 1.46M | 1.41M | 2.74M | 2.61M | 2.10M | 2.26M | 2.21M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.34M | 1.40M | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 151.72K | 574.35K | 0.00 | 0.00 | 0.00 |
| SG&A | 10.69M | 20.45M | 14.85M | 24.21M | 26.48M | 2.70M | 1.46M | 1.41M | 2.74M | 2.61M | 2.10M | 2.26M | 2.21M | 2.35M | 2.21M | 2.29M | 2.41M | 1.92M | 2.03M | 2.91M | 1.48M | 1.94M | 1.49M | 1.97M | 982.40K | 0.00 | 0.00 |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -115.87K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -10.37K | -7.81K |
| Operating Expenses | 34.42M | 66.02M | 29.44M | 50.56M | 46.97M | 19.10M | 2.14M | 3.79M | 7.74M | 7.02M | 4.59M | 5.29M | 6.09M | 4.99M | 4.56M | 4.06M | 3.62M | 3.49M | 3.45M | 4.05M | 2.28M | 2.31M | 1.97M | 2.45M | 1.16M | -10.37K | -7.81K |
| Cost & Expenses | 34.42M | 66.02M | 29.44M | 50.56M | 46.97M | 19.10M | 2.14M | 3.79M | 7.74M | 7.02M | 4.59M | 5.29M | 6.09M | 4.99M | 4.56M | 4.06M | 3.62M | 3.49M | 3.45M | 4.05M | 2.28M | 2.31M | 1.97M | 2.45M | 1.16M | -10.37K | -7.81K |
| Interest Income | 274.00K | 8.00K | 337.00K | 1.07M | 601.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.48K | 0.00 | 0.00 | 43.08K | 100.45K | 69.30K | 0.00 | 54.03K | 0.00 | 0.00 | 24.26K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.95M | 1.26M | 1.41M | 1.62M | 7.00K | 43.00K | 265.20K | 533.00 | 2.77K | 77.44K | 119.09K | 134.55K | 88.12K | 610.67K | 1.01M | 434.15K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 695.00K | 960.00K | 571.00K | 559.00K | 216.00K | 39.00K | 44.08K | 93.39K | 177.07K | 349.66K | 293.63K | 258.02K | 143.27K | 126.57K | 111.75K | 96.85K | 166.17K | 40.11K | 43.72K | 30.42K | 38.70K | 24.36K | 24.16K | 18.71K | 4.00K | 0.00 | 0.00 |
| EBITDA | -33.37M | -66.02M | -33.46M | -50.56M | -46.15M | -20.39M | -4.59B | -8.85M | -17.88M | -8.80M | -4.65B | -4.83M | -6.33B | -4.72M | -4.17M | -3.50M | -3.15M | -3.38M | -3.28M | -4.01M | -2.23M | -2.09M | -1.95M | -2.43M | -1.15M | -10.37K | -7.81K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -4,827.52% | -9,982.48% | -6,572.38% | 0.00% | -2,491.85% | 0.00% | 2,290.26% | -1,343.62% | -620.45% | -1,051.61% | -5,068.89% | -2,853.45% | -25,703.22% | -23,608.61% | -1,120.21% | -200,724,000.00% | -242,873,500.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -34.42M | -66.02M | -33.46M | -50.56M | -47.57M | -20.39M | -4.59M | -11.19M | -18.08M | -9.15M | -4.65M | -5.41M | -7.92M | -4.85M | -4.28M | -3.60M | -3.32M | -3.42M | -3.32M | -4.04M | -2.27M | -2.11M | -1.97M | -2.45M | -1.16M | -10.37K | -7.81K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -14,926.64% | -24,102.31% | -9,147.80% | 0.00% | -2,705.76% | 0.00% | -3,461.80% | -1,558.07% | -788.11% | -1,107.00% | -5,129.06% | -2,657.39% | -24,223.34% | -22,686.06% | -1,057.12% | -197,107,000.00% | -244,744,800.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -1.65M | -709.00K | -1.12M | -319.00K | 502.00K | -824.00K | -2.24M | 2.25M | 12.95K | -77.44K | -1.47M | 345.40K | 649.73K | 4.85M | 4.28M | 3.60M | 3.32M | 3.42M | 1.13M | 959.02K | 130.95K | 150.55K | 60.33K | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -36.07M | -66.73M | -34.58M | -50.87M | -47.06M | -21.21M | -6.84M | -8.95M | -18.06M | -9.23M | -6.12M | -5.07M | -7.27M | -12.77M | -4.76M | -4.27M | 0.00 | 0.00 | -3.03M | -3.76M | -2.14M | -1.96M | -1.91M | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -11,930.57% | -24,085.05% | -9,225.23% | 0.00% | -2,533.07% | 0.00% | -9,123.46% | -1,731.89% | -934.55% | 0.00% | 0.00% | -2,426.36% | -22,560.92% | -21,376.54% | -981.84% | -191,073,900.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 1.26M | 1.41M | 1.62M | 122.00K | 43.00K | -1.04M | -680.00K | 2.77K | 77.44K | 119.09K | -24.26K | 1.07M | 8.54M | 1.44M | 1.00M | -69.30K | -104.46K | -342.82K | -310.35K | -202.27K | -174.81K | -94.08K | -2.53K | 13.14K | 10.37K | 7.81K |
| Net Income | -36.07M | -66.73M | -34.58M | -50.87M | -47.19M | -21.21M | -5.80M | -8.27M | -18.06M | -9.23M | -6.12M | -5.07M | -7.27M | -13.38M | -5.73M | -4.60M | -3.25M | -3.31M | -2.98M | -3.73M | -2.07M | -1.94M | -1.88M | -2.44M | -1.17M | -10.37K | -7.81K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -11,023.91% | -24,085.05% | -9,225.23% | 0.00% | -2,533.07% | 0.00% | -9,559.65% | -2,082.50% | -1,007.62% | -1,083.90% | -4,972.38% | -2,383.13% | -22,361.26% | -20,663.38% | -969.71% | -187,699,100.00% | -244,491,600.00% | 0.00% | 0.00% | 0.00% |
| EPS | -16.65 | -38.15 | -34.47 | -53.46 | -58.19 | -170.52 | -199.71 | -325.47 | -1.00K | -1.35K | -3.59K | -4.73K | -7.48K | -21.38K | -23.19K | -20.18K | -14.92K | -17.18K | -15.43K | -21.80K | -13.96K | -13.10K | -19.15K | -24.95K | -655.27 | -134.73 | -101.43 |
| EPS Diluted | -16.65 | -38.15 | -34.47 | -53.46 | -58.19 | -170.52 | -199.71 | -325.47 | -1.00K | -1.35K | -3.59K | -4.73K | -7.48K | -21.38K | -23.19K | -20.18K | -14.92K | -17.18K | -15.43K | -21.80K | -13.96K | -13.10K | -19.15K | -24.95K | -655.27 | -134.73 | -101.43 |
| Weighted Avg Shares Out | 2.17M | 1.75M | 1.00M | 951.58K | 810.91K | 124.41K | 29.02K | 25.40K | 18.02K | 6.85K | 1.71K | 1.07K | 972.00 | 626.00 | 247.00 | 228.00 | 218.00 | 193.00 | 193.00 | 171.00 | 148.00 | 148.00 | 98.00 | 98.00 | 1.78K | 77.00 | 77.00 |
| Weighted Avg Shares Out (Dil) | 2.17M | 1.75M | 1.00M | 951.58K | 810.91K | 124.41K | 29.02K | 25.40K | 18.02K | 6.85K | 1.71K | 1.07K | 972.00 | 626.00 | 247.00 | 228.00 | 218.00 | 193.00 | 193.00 | 171.00 | 148.00 | 148.00 | 98.00 | 98.00 | 1.78K | 77.00 | 77.00 |
Zacks: Senesco Technologies Inc. (NYSE:ELOX) Given $13.75 Average Target Price by Analysts
Senesco Technologies Inc. (NYSE:ELOX) has been given an average broker rating score of 1.50 (Buy) from the four brokers that provide coverage for the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold...
Eloxx Pharmaceuticals Provides Update on Progress of Its Phase 2 Clinical Programs for ELX-02 and ERSG Pipeline at Biotech Showcase™
Phase 2 cystic fibrosis program for ELX-02 expected to be fully enrolled in the first quarter of 2020 and topline results expected during the first half of...
Source: https://incomestatements.info
Category: Stock Reports